Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 27, Issue 5, 2004, Pages 355-359

  Kuroha, M ^a   Shirai, Y ^a   Shimoda, Minoru ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; KETOCONAZOLE; QUINIDINE;

ANIMAL EXPERIMENT; ARTICLE; DISTRIBUTION VOLUME; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; ENZYME SUBSTRATE; LIVER CLEARANCE; MALE; METABOLIC INHIBITION; MULTIPLE DRUG DOSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG ADMINISTRATION SCHEDULE; DRUG ANTAGONISM; ENZYME INHIBITORS; INJECTIONS, INTRAVENOUS; KETOCONAZOLE; MALE; QUINIDINE;

ANIMALIA; CANIS FAMILIARIS; STAPHYLOCOCCUS PHAGE 3A;

EID: 8344226085     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2004.00610.x     Document Type: Article

References (22)

1. Angarano, D.W. & Scott, D.W. (1987) Use of ketoconazole in treatment of dermatophytosis in a dog. Journal of the American Veterinary Medical Association, 190, 1433-1434.
2. Arboix, M., Paz, O.G., Colombo, T., & D'Incalci, M. (1997) Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. The Journal of Pharmacology and Experimental Therapeutics, 281, 1226-1230.
3. Bourrie, M., Meunier, V., Berger, Y. & Fahre, G. (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. The Journal of Pharmacology and Experimental Therapeutics, 277, 321-332.
4. Boxenbaum, H. (1980) Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmaceutics, 8, 165-176.
5. Clohisy, D.R., & Gibson, T.P. (1982) Comparison of pharmacokinetic parameters of intravenous quinidine and quinine in dogs. Journal of Cardiovascular Pharmacology, 4, 107-110.
6. Edstein, M.D., Prasitthipayong, A., Sabchareon, A., Chongsuphajaisiddhi, T., & Webster, H.K. (1990) Simultaneous measurement of quinine and quinidine in human plasma, whole blood, and erythrocytes by high-performance liquid chromatography with fluorescence detection. Therapeutic Drug Monitoring, 12, 493-500.
7. Feldman, B.C., Bruyette, D.S., Nelson, R.W. & Farver, T.B. (1990) Plasma cortisol response to ketoconazole administration in dogs with hyper-adrenocorticism. Journal of the American Veterinary Medical Association, 197, 71-78.
8. Floren, L.C., Bekersky, I., Benet, L.Z., Mekki, Q., Dressier. D., Lee, J.W., Roberts, J.P. & Hebert, M.F. (1997) Tacrolimus oral bioavailability doubles with co-administration of ketoconazole. Clinical Pharmacology and Therapeutics. 62, 41-49.
9. Gomez, D.Y., Wacher, V.J., Tomlanovich, S.J., Hebert, M.F. & Benet, L.Z. (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clinical Pharmacology and Therapeutics, 58, 15-19.
10. Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H. & Sugiyama, Y. (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacological Reviews, 50, 387-412.
11. Kim, R.B., Wandel, C., Leake, B. et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmaceutical Research, 16, 408-414.
12. Kuroha, M., Kuze, Y., Shimoda, M. & Kokue, E. (2002a) In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. American Journal of Veterinary Research, 63, 900-905.
13. Kuroha, M., Azumano, A., Kuze, Y., Shimoda, M. & Kokue, E. (2002b) Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. Drug Metabolism and Disposition, 30, 63-68.
14. Kuroha, M., Kayaba, H., Kishimoto, S., Khalil, W.F., Shimoda, M. & Kokue, E. (2002c) Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs. Journal of Pharmaceutical Sciences, 91, 868-873.
15. Kusuhara, H., Suzuki, H., Terasaki, T., Kakee, A., Lemaire, M. & Sugiyama, Y. (1997) P-glycoprotein mediates the efflux of quinidine across the blood-brain barrier. The Journal of Pharmacology and Experimental Therapeutics, 283, 574-580.
16. Legendre, A.M., Selcer, B.A., Edwards, D.F. & Stevens. R. (1984) Treatment of canine blastomycosis with amphotericin B and ketoconazole. Journal of the American Veterinary Medical Association, 184, 1249-1254.
17. Mason, G.D., Labato, M.A. & Bachrach, A. Jr. (1989) Ketoconazole therapy in a dog with systemic cryptococcosis. Journal of the American Veterinary Medical Association. 195, 954-956.
18. Maurice, M., Pichard, L., Daujat, M., Fabre, I., Joyeux, H., Domergue, J. & Maurel, P. (1992) Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. The FASEB Journal. 6, 752-758.
19. Newton, D.J., Wang, R.W. & Lu, A.Y. (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
20. Sharp, N.J. & Sullivan, M. (1989) Use of ketoconazole in the treatment of canine nasal aspergillosis. Journal of the American Veterinary Medical Association, 194, 782-786.
21. Woodland, C., Ito, S. & Koren, G. (1998) A model for the prediction of digoxin-drug interactions at the renal tubular cell level. Therapeutic Drug Monitoring. 20, 134-138.
22. Yamaoka, K., Tanigawara, Y., Nakagawa, T. & Uno, T. (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Phannacobio-dynamics, 4, 879-885.